Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The firm is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. Its technologies include iBioLaunch technology and iBioModulator. The firm`s technologies constitute a transformative platform for development and production of biologics in hydroponically grown green plants. The firm is focused on the commercialization of its plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The firm`s technology is applicable in a range of product candidates, including products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are derived from human blood plasma.
Website: ibioinc.com



Growth: Bad revenue growth rate 0.0%, there is slowdown compared to average historical growth rates 8.3%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -3 400.0%. Gross margin is high, +75.4%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 25% of quarters (showing a gain of -$0.11 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -42.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 1 930.0% higher than minimum and 90.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -163.8x by EV / Sales multiple

Key Financials (Download financials)

Ticker: IBIO
Share price, USD:  (+20.8%)4.06
year average price 0.85  


year start price 2.08 2023-03-31

min close price 0.20 2023-11-28

max close price 4.06 2024-03-28

current price 4.06 2024-03-29
Common stocks: 23 968 999

Dividend Yield:  0.0%
Last revenue growth (y/y):  0.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  8.3%
Historical growth of EBITDA:  0.0%
EV / Sales: 40.2x
Margin (EBITDA LTM / Revenue): -3 400.0%
Fundamental value created in LTM:
Market Cap ($m): 97
Net Debt ($m): -17
EV (Enterprise Value): 80
Price to Book: 8.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-03-27Invezz

iBio stock nearly tripled on Wednesday: here's why

2024-03-27Proactive Investors

iBio partners with AstralBio to develop obesity treatments using AI-driven platform

2024-03-27InvestorPlace

Why Is iBio (IBIO) Stock Up 125% Today?

2023-12-05InvestorPlace

Why Is iBio (IBIO) Stock Down 41% Today?

2023-06-13InvestorPlace

Why Is iBio (IBIO) Stock Up 16% Today?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IBIO IBIO IBIO IBIO IBIO IBIO
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-09 2023-09-30 2023-09-27 2023-05-15 2023-02-14 2022-11-14
acceptedDate 2024-02-09 16:06:07 2023-09-29 20:00:00 2023-09-27 16:01:58 2023-05-15 09:27:55 2023-02-14 17:27:28 2022-11-14 17:25:30
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2 Q1
revenue 0 50 000 0 0 0 0
costOfRevenue 387 000 250 000 0 0 0 0
grossProfit -387 000 -200 000 0 0 0 0
grossProfitRatio 0 -4.000 0 0 0 0
researchAndDevelopmentExpenses 2M 2M 2M 3M 3M 3M
generalAndAdministrativeExpenses 3M 4M 3M 4M 8M 5M
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 3M 4M 3M 4M 8M 5M
otherExpenses 0 0 0 -98 000 0 0
operatingExpenses 4M 5M 5M 6M 11M 8M
costAndExpenses 4M 5M 5M 6M 11M 8M
interestIncome 42 000 55 000 50 000 23 000 41 000 99 000
interestExpense 34 000 26 000 17 000 35 000 31 000 99 000
depreciationAndAmortization 319 000 318 000 305 000 207 000 340 000 494 000
ebitda -4M -5M -5M -6M -10M -7M
ebitdaratio 0 -94.600 0 0 0 0
operatingIncome -4M -5M -5M -6M -11M -8M
operatingIncomeRatio 0 -102.060 0 0 0 0
totalOtherIncomeExpensesNet -4M 29 000 33 000 -110 000 10000.000 99 000
incomeBeforeTax -4M -5M -5M -6M -11M -8M
incomeBeforeTaxRatio 0 -101.480 0 0 0 0
incomeTaxExpense 34 000 727 000 1M 35 000 23M 10M
netIncome -8M -6M -6M -6M -34M -18M
netIncomeRatio 0 -114.920 0 0 0 0
eps -4.420 -0.240 -0.350 -0.480 -3.420 -2.040
epsdiluted -4.420 -0.240 -0.350 -0.480 -3.420 -2.040
weightedAverageShsOut 2M 24M 17M 13M 10M 9M
weightedAverageShsOutDil 2M 24M 17M 13M 10M 9M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IBIO IBIO IBIO IBIO IBIO IBIO
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-09 2023-09-30 2023-09-27 2023-05-15 2023-02-14 2022-11-14
acceptedDate 2024-02-09 16:06:07 2023-09-29 20:00:00 2023-09-27 16:01:58 2023-05-15 09:27:55 2023-02-14 17:27:28 2022-11-14 17:25:30
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2 Q1
cashAndCashEquivalents 3M 1M 4M 7M 4M 10M
shortTermInvestments 0 0 0 0 6M 8M
cashAndShortTermInvestments 3M 1M 4M 7M 10M 17M
netReceivables 2M 0 204 000 1M 8M 6M
inventory 14M 0 21M 18M 20M 0
otherCurrentAssets 894 000 451 000 664 000 921 000 414 000 40M
totalCurrentAssets 20M 23M 26M 27M 38M 64M
propertyPlantEquipmentNet 7M 7M 8M 8M 8M 7M
goodwill 0 0 0 0 0 0
intangibleAssets 5M 5M 5M 5M 5M 6M
goodwillAndIntangibleAssets 5M 5M 5M 5M 5M 6M
longTermInvestments 2M 2M 0 0 0 0
taxAssets -2M -2M 0 0 0 0
otherNonCurrentAssets 2M 2M 2M 4M 303 000 8M
totalNonCurrentAssets 14M 15M 15M 17M 14M 21M
otherAssets 0 0 0 0 0 0
totalAssets 34M 38M 41M 44M 52M 85M
accountPayables 2M 2M 2M 2M 4M 5M
shortTermDebt 13M 13M 14M 14M 17M 23M
taxPayables 0 0 268 000 0 0 0
deferredRevenue 4M 4M 4M 0 88 000 161 000
otherCurrentLiabilities 2M 2M 2M 6M 7M 5M
totalCurrentLiabilities 22M 21M 22M 22M 28M 32M
longTermDebt 3M 3M 3M 4M 4M 4M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 155 000 461 000 768 000 1M 1M -24M
totalNonCurrentLiabilities 3M 4M 4M 5M 5M 4M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 4M 4M 4M 4M 4M 4M
totalLiabilities 25M 24M 26M 27M 33M 36M
preferredStock 0 0 0 0 0 0
commonStock 30 000 28 000 20 000 16 000 12 000 9000.000
retainedEarnings -303M -295M -289M -283M -276M -242M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 -167 000 -223 000
othertotalStockholdersEquity 312M 308M 304M 300M 295M 291M
totalStockholdersEquity 9M 13M 15M 17M 19M 48M
totalEquity 9M 13M 15M 17M 19M 48M
totalLiabilitiesAndStockholdersEquity 34M 38M 41M 44M 52M 85M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 34M 38M 41M 44M 52M 85M
totalInvestments 2M 2M 0 0 6M 8M
totalDebt 16M 17M 17M 18M 20M 27M
netDebt 14M 15M 13M 11M 17M 17M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IBIO IBIO IBIO IBIO IBIO IBIO
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-09 2023-09-30 2023-09-27 2023-05-15 2023-02-14 2022-11-14
acceptedDate 2024-02-09 16:06:07 2023-09-29 20:00:00 2023-09-27 16:01:58 2023-05-15 09:27:55 2023-02-14 17:27:28 2022-11-14 17:25:30
calendarYear 2024.000 2024.000 2023.000 2023.000 2023.000 2023.000
period Q2 Q1 Q4 Q3 Q2 Q1
netIncome -8M -6M -6M -7M -34M -18M
depreciationAndAmortization 319 000 318 000 305 000 282 000 299 000 494 000
deferredIncomeTax 3M -50 000 259 000 0 0 0
stockBasedCompensation 456 000 765 000 446 000 2M 1M 1M
changeInWorkingCapital -120 000 -695 000 -10000.000 2M 5M -2M
accountsReceivables 0 0 69 000 900 000 85 000 -54 000
inventory 0 0 0 43 000 79 000 -1M
accountsPayables -51 000 62 000 -144 000 -2M 1M 166 000
otherWorkingCapital -69 000 -757 000 65 000 3M 4M -677 000
otherNonCashItems -250 000 68 000 63 000 -677 000 19M 4M
netCashProvidedByOperatingActivities -5M -5M -5M -4M -8M -14M
investmentsInPropertyPlantAndEquipment 0 0 -506 000 201 000 -3M -2M
acquisitionsNet 0 50 000 0 0 0 -692 000
purchasesOfInvestments 0 0 0 0 -692 000 0
salesMaturitiesOfInvestments 0 0 0 6M 2M 3M
otherInvestingActivites 0 0 500 000 2M 692 000 0
netCashUsedForInvestingActivites 0 50 000 -6000.000 8M -1M 29 000
debtRepayment -107 000 -540 000 -896 000 -2M -6M -10000.000
commonStockIssued 4M 3M 4M 4M 3M 1M
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites -7000.000 116 000 0 0 439 000 0
netCashUsedProvidedByFinancingActivities 4M 2M 3M 1M -3M 1M
effectOfForexChangesOnCash 0 0 0 33 000 0 0
netChangeInCash -701 000 -3M -2M 6M -12M -13M
cashAtEndOfPeriod 4M 5M 8M 10M 4M 16M
cashAtBeginningOfPeriod 5M 8M 10M 4M 16M 29M
operatingCashFlow -5M -5M -5M -4M -8M -14M
capitalExpenditure 0 0 -506 000 201 000 -3M -2M
freeCashFlow -5M -5M -5M -4M -11M -16M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Earning call transcript

2022 q2
2022-09-27 ET (fiscal 2022 q4)
2022 q1
2022-05-12 ET (fiscal 2022 q3)
2021 q4
2022-02-14 ET (fiscal 2022 q2)

Press-releases

Show financial reports only

2023-12-26 12:15 ET
iBio Amends and Extends Maturity of Credit Agreement
2023-12-05 13:00 ET
iBio, Inc. Announces Pricing of $4.5 Million Public Offering
2023-11-27 22:20 ET
iBio Announces Reverse Stock Split
2023-11-01 12:24 ET
iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific
2023-10-10 12:00 ET
iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics
2023-10-02 10:45 ET
iBio Explains Recent Filing of Registration Statement
2023-09-27 20:19 ET
iBio Announces Filing of 2023 Annual Report on SEC Form 10-K
2023-09-21 20:05 ET
iBio Announces Amendment to Credit Agreement with Woodforest
2023-08-14 20:15 ET
iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development
2023-06-27 12:00 ET
iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company’s Next Stage of Growth
2023-06-12 20:15 ET
iBio Forges Research Collaboration with the National Institutes of Health
2023-06-06 12:00 ET
iBio Expands Tech Stack with EngageTx™; Adds TROP-2 Bispecific to Development Pipeline
2023-05-09 20:30 ET
iBio to Participate in the JMP Securities Life Sciences Conference
2023-04-04 20:05 ET
iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform
2023-03-31 12:10 ET
iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing
2023-02-16 21:47 ET
iBio Announces MUC16 as its Latest Immune-Oncology Target Program
2023-01-05 13:00 ET
iBio Announces Issuance of U.S. Patent Covering AI-Engineered Epitope Discovery Engine
2022-12-09 21:05 ET
iBio Announces Closing of $3.5 Million Underwritten Public Offering
2022-12-07 04:27 ET
iBio Announces Pricing of $3.5 Million Underwritten Public Offering
2022-12-06 21:01 ET
iBio Announces Proposed Underwritten Public Offering
2022-12-06 13:00 ET
iBio to Participate in the JMP Securities Hematology and Oncology Summit
2022-12-05 13:00 ET
iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022
2022-12-02 21:30 ET
iBio Announces CEO Departure
2022-11-03 12:00 ET
iBio Accelerates Transformation to AI-Powered Biotech
2022-09-27 20:10 ET
iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update
2022-09-21 12:30 ET
iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline
2022-08-16 13:00 ET
iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate
2022-05-18 12:00 ET
iBio to Participate in the H.C. Wainwright Global Investment Conference
2022-05-12 20:05 ET
iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update
2022-05-09 12:00 ET
iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer
2022-05-05 20:30 ET
iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022
2022-05-02 12:00 ET
iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants
2022-03-11 13:00 ET
iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference
2022-02-15 13:00 ET
Pipeline Therapeutics Appoints Eef Schimmelpennink to its Board of Directors
2022-02-14 21:05 ET
iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update
2022-02-07 21:30 ET
iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022
2022-01-26 14:00 ET
iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease
2022-01-04 21:30 ET
iBio Announces Participation in the H.C. Wainwright BioConnect Conference
2021-12-22 14:25 ET
iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022
2021-12-21 14:20 ET
iBio Provides Information for Listening to the Virtual Annual Stockholder Meeting
2021-12-10 13:30 ET
iBio Announces Partial Adjournment of Annual Meeting to December 22
2021-11-30 13:00 ET
ISS Joins Glass Lewis in Recommending Shareholders Vote “FOR” All Proposals Ahead of iBio’s Upcoming Annual Meeting
2021-11-29 13:45 ET
Omicron Variant Underscores Need for New COVID Vaccine Candidates Like IBIO-202
2021-11-17 21:30 ET
Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote “FOR” All Proposals Ahead of Annual Meeting
2021-11-15 21:05 ET
iBio Reports Fiscal First Quarter 2022 Financial Results and Provides Corporate Update
2021-11-15 18:00 ET
iBio Announces Collaboration with UT Southwestern to Investigate IBIO-100 in Solid Tumors
2021-11-08 21:30 ET
iBio to Report Fiscal 2022 First Quarter Financial Results and Provide Corporate Update on Monday, November 15, 2021
2021-11-03 20:47 ET
iBio Acquires FastPharming Manufacturing Facility®
2021-10-26 12:35 ET
iBio Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting to be Held on December 9
2021-09-27 11:30 ET
iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update
2021-09-20 20:30 ET
iBio to Participate in the Cantor 2021 Virtual Global Healthcare Conference
2021-09-20 11:30 ET
iBio to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Monday, September 27, 2021
2021-09-07 20:30 ET
iBio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference
2021-08-26 11:00 ET
iBio Appoints William D. Clark to its Board of Directors
2021-08-25 11:30 ET
iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics
2021-07-15 21:10 ET
iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate
2021-07-08 20:15 ET
iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs
2021-06-09 20:30 ET
iBio Further Strengthens Board with Appointment of Veteran Biopharmaceutical Executive, Eef Schimmelpennink
2021-05-19 20:30 ET
iBio to Present at the UBS Global Healthcare Virtual Conference
2021-05-17 11:00 ET
iBio Reports Fiscal Third Quarter 2021 Financial Results and Provides Corporate Update
2021-05-10 12:15 ET
iBio to Report Fiscal 2021 Third Quarter Financial Results and Provide Corporate Update on Monday, May 17, 2021
2021-05-06 20:15 ET
iBio Reports Successful COVID-19 Vaccine Toxicology Study Results and Announces Next-Gen COVID-19 Vaccine Program
2021-05-04 21:00 ET
iBio and Fraunhofer USA Conclude Litigation and Enter License Agreement
2021-03-09 21:30 ET
iBio to Participate in the 33rd Annual Roth Conference
2021-02-16 21:05 ET
iBio Reports Fiscal Second Quarter 2021 Financial Results and Provides Corporate Update
2021-02-16 13:00 ET
iBio Appoints Robert M. Lutz as Chief Financial & Business Officer
2021-02-09 21:30 ET
iBio to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Update on Tuesday, February 16, 2021
2020-12-28 12:30 ET
iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer
2020-12-10 21:30 ET
iBio Announces Closing of its Public Offering of Common Stock
2020-12-08 13:55 ET
iBio Announces Pricing of $35 Million Public Offering of Common Stock
2020-12-07 21:01 ET
iBio Announces Proposed Public Offering of Common Stock
2020-12-01 21:30 ET
iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins
2020-11-24 12:30 ET
iBio Announces Issuance of U.S. Patent Covering Endostatin Peptides for Treating Fibrosis
2020-11-16 21:05 ET
iBio Reports Fiscal First Quarter 2021 Financial Results and Provides Corporate Update
2020-11-12 13:00 ET
iBio to Participate in Alliance Global Partners’ Virtual Healthcare Symposium
2020-11-05 21:30 ET
iBio to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Update on Monday, November 16 ,2020
2020-11-03 12:30 ET
iBio Announces Appointment of Randy J. Maddux as Chief Operating Officer
2020-10-15 20:05 ET
Accomplished Financial Executive, Gary Sender, Joins iBio’s Board of Directors
2020-10-15 11:30 ET
iBio Announces Appointment of Dr. Alexandra Kropotova to Board of Directors
2020-10-14 20:05 ET
iBio Announces Appointment of Dr. Linda Armstrong to Board of Directors
2020-10-13 20:05 ET
iBio Announces Financial Results for Fiscal Year Ended June 30, 2020
2020-10-05 11:30 ET
iBio Regains Compliance with NYSE American Continued Listing Standards
2020-10-02 11:00 ET
iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming® System
2020-09-09 12:45 ET
iBio to Advance COVID-19 LicKM-Subunit Vaccine Candidate, IBIO-201
2020-08-28 11:15 ET
iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement for the Development of a COVID-19 Therapeutic
2020-08-10 11:15 ET
iBio Provides Update on IBIO-201 COVID-19 Vaccine Program
2020-06-26 10:45 ET
iBio to be Added to the Russell 2000® and Russell 3000® Indexes
2020-06-24 10:45 ET
iBio Selected by IBM Watson Health for the use of IBM Clinical Development Solution at No Cost to help Support clinical COVID-19 Vaccine Candidates
2020-06-04 11:00 ET
iBio Announces Second COVID-19 Vaccine Program
2020-04-27 20:15 ET
iBio Estimates ~500 Million Dose Capacity for COVID-19 Vaccine from its FastPharming Facility™
2020-04-09 11:30 ET
iBio Expands COVID-19 Vaccine Collaboration to Include the Infectious Disease Research Institute
2020-03-26 20:20 ET
iBio Supporting AzarGen Biotechnologies’ Development of a Rituximab Biosimilar
2020-03-26 11:30 ET
iBio Announces Advancement of COVID-19 Vaccine Program
2020-03-20 11:30 ET
iBio Joins the Alliance for Biosecurity
2020-03-18 12:00 ET
iBio Announces Development of Proprietary COVID-19 Vaccine Candidates
2020-03-12 20:45 ET
iBio Announces Leadership Succession, Appoints Thomas F. Isett Co-Chairman & CEO
2020-03-02 21:30 ET
iBio, Inc. Announces Withdrawal of Proxy Statement Proposal to Amend Its Certificate of Incorporation to Authorize a Possible Reverse Stock Split
2020-02-06 21:30 ET
iBio, Inc. Announces Postponement of Annual Meeting
2020-02-03 21:15 ET
iBio and CC-Pharming Initiate Joint Development of Coronavirus Vaccine
2020-01-16 13:00 ET
iBio, Inc. Announces NYSE American Acceptance of Plan of Compliance
2020-01-06 14:15 ET
iBio Initiates New Litigation Against Fraunhofer
2019-12-23 13:30 ET
iBio Announces Collaboration with EdgePoint AI for Next Gen Quality in Biologics Manufacturing
2019-12-16 21:15 ET
iBio Reports Progress on its Bio-Better Rituximab Collaboration with CC-Pharming
2019-12-13 22:00 ET
iBio, Inc. Reports on NYSE American Noncompliance Notice and Compliance Plan
2019-12-10 21:44 ET
iBio Introduces FastGlycaneering Development Service™ to Power Recombinant Protein Production
2019-12-03 17:31 ET
iBio Joins Manufacturing USA’s Tissue Biofabrication Initiative
2019-12-02 21:15 ET
iBio to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference

SEC forms

Show financial reports only

SEC form 10
2024-02-09 00:00 ET
iBio reported for 2023 q4
SEC form 10
2023-11-14 00:00 ET
iBio reported for 2023 q3
SEC form 10
2023-09-27 00:00 ET
iBio reported for 2023 q2
SEC form 8
2023-09-27 00:00 ET
iBio published news for 2023 q2
SEC form 6
2023-08-07 16:01 ET
iBio published news for 2023 q2
SEC form 6
2023-08-04 16:47 ET
iBio published news for 2023 q2
SEC form 6
2023-07-10 08:29 ET
iBio published news for 2023 q2
SEC form 6
2023-06-27 08:00 ET
iBio published news for 2023 q1
SEC form 6
2023-06-20 08:59 ET
iBio published news for 2023 q1
SEC form 10
2023-05-15 00:00 ET
iBio reported for 2023 q1
SEC form 6
2023-04-03 16:00 ET
iBio published news for 2023 q1
SEC form 6
2023-03-30 16:44 ET
iBio published news for 2022 q4
SEC form 6
2023-03-13 08:20 ET
iBio published news for 2022 q4
SEC form 6
2023-02-21 16:31 ET
iBio published news for 2022 q4
SEC form 6
2023-02-16 17:02 ET
iBio published news for 2022 q4
SEC form 10
2023-02-14 17:27 ET
iBio reported for 2022 q4
SEC form 10
2023-02-14 00:00 ET
iBio reported for 2022 q4
SEC form 6
2023-01-25 16:00 ET
iBio published news for 2022 q4
SEC form 6
2023-01-17 09:00 ET
iBio published news for 2022 q4
SEC form 6
2022-12-09 16:03 ET
iBio published news for 2022 q3
SEC form 6
2022-12-08 16:13 ET
iBio published news for 2022 q3
SEC form 6
2022-12-07 16:32 ET
iBio published news for 2022 q3
SEC form 6
2022-12-02 16:26 ET
iBio published news for 2022 q3
SEC form 10
2022-11-14 17:25 ET
iBio reported for 2022 q3
SEC form 10
2022-11-14 00:00 ET
iBio reported for 2022 q3
SEC form 6
2022-11-03 16:02 ET
iBio published news for 2022 q3
SEC form 6
2022-11-03 08:00 ET
iBio published news for 2022 q3
SEC form 6
2022-10-26 16:00 ET
iBio published news for 2022 q3
SEC form 6
2022-10-20 16:00 ET
iBio published news for 2022 q3
SEC form 6
2022-10-14 16:13 ET
iBio published news for 2022 q3
SEC form 10
2022-10-11 16:39 ET
iBio reported for 2022 q2
SEC form 10
2022-10-11 00:00 ET
iBio reported for 2022 q2
SEC form 6
2022-10-07 16:01 ET
iBio published news for 2022 q3
SEC form 6
2022-10-03 16:12 ET
iBio published news for 2022 q3
SEC form 6
2022-09-29 16:00 ET
iBio published news for 2022 q2
SEC form 6
2022-09-27 16:11 ET
iBio published news for 2022 q2
SEC form 8
2022-09-27 00:00 ET
iBio published news for 2022 q2
SEC form 6
2022-09-21 08:28 ET
iBio published news for 2022 q2
SEC form 6
2022-08-16 09:03 ET
iBio published news for 2022 q2
SEC form 6
2022-07-06 10:05 ET
iBio published news for 2022 q2
SEC form 6
2022-05-23 17:32 ET
iBio published news for 2022 q1
SEC form 6
2022-05-13 18:11 ET
iBio published news for 2022 q1
SEC form 6
2022-05-13 08:48 ET
iBio published news for 2022 q1
SEC form 10
2022-05-12 16:17 ET
iBio reported for 2022 q1
SEC form 6
2022-05-12 16:10 ET
iBio published news for 2022 q1
SEC form 6
2022-05-12 16:02 ET
iBio published news for 2022 q1
SEC form 6
2022-05-12 16:00 ET
iBio published news for 2022 q1
SEC form 8
2022-05-12 00:00 ET
iBio reported for 2022 q1
SEC form 10
2022-05-12 00:00 ET
iBio reported for 2022 q1
SEC form 6
2022-05-02 16:01 ET
iBio published news for 2022 q1
SEC form 6
2022-03-18 16:04 ET
iBio published news for 2021 q4
SEC form 6
2022-02-14 16:35 ET
iBio published news for 2021 q4
SEC form 10
2022-02-14 16:21 ET
iBio published news for 2021 q4
SEC form 8
2022-02-14 00:00 ET
iBio published news for 2021 q4
SEC form 10
2022-02-14 00:00 ET
iBio published news for 2021 q4
SEC form 6
2022-02-01 06:31 ET
iBio published news for 2021 q4
SEC form 6
2022-02-01 06:08 ET
iBio published news for 2021 q4
SEC form 6
2022-01-31 17:18 ET
iBio published news for 2021 q4
SEC form 6
2022-01-26 09:15 ET
iBio published news for 2021 q4
SEC form 6
2021-12-22 11:52 ET
iBio published news for 2021 q3
SEC form 6
2021-12-10 09:01 ET
iBio published news for 2021 q3
SEC form 10
2021-11-15 16:18 ET
iBio published news for 2021 q3
SEC form 6
2021-11-15 16:15 ET
iBio published news for 2021 q3
SEC form 8
2021-11-15 00:00 ET
iBio published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
iBio published news for 2021 q3
SEC form 6
2021-11-04 16:16 ET
iBio published news for 2021 q3
SEC form 6
2021-10-26 08:30 ET
iBio published news for 2021 q3
SEC form 6
2021-10-13 16:06 ET
iBio published news for 2021 q3
SEC form 10
2021-09-28 16:11 ET
iBio published news for 2021 q2
SEC form 10
2021-09-28 00:00 ET
iBio published news for 2021 q2
SEC form 6
2021-09-27 07:45 ET
iBio published news for 2021 q2
SEC form 6
2021-08-31 16:30 ET
iBio published news for 2021 q2
SEC form 6
2021-08-30 06:03 ET
iBio published news for 2021 q2
SEC form 6
2021-08-27 07:32 ET
iBio published news for 2021 q2
SEC form 6
2021-08-26 07:10 ET
iBio published news for 2021 q2
SEC form 6
2021-07-16 06:01 ET
iBio published news for 2021 q2
SEC form 6
2021-06-09 17:18 ET
iBio published news for 2021 q1
SEC form 10
2021-05-17 16:34 ET
iBio published news for 2021 q1
SEC form 6
2021-05-17 07:15 ET
iBio published news for 2021 q1
SEC form 10
2021-05-17 00:00 ET
iBio published news for 2021 q1
SEC form 6
2021-05-06 16:45 ET
iBio published news for 2021 q1
SEC form 6
2021-05-04 17:15 ET
iBio published news for 2021 q1
SEC form 6
2021-02-16 16:14 ET
iBio published news for 2020 q4
SEC form 10
2021-02-16 16:12 ET
iBio published news for 2020 q4
SEC form 6
2021-02-16 08:05 ET
iBio published news for 2020 q4
SEC form 6
2021-01-12 16:05 ET
iBio published news for 2020 q4
SEC form 6
2020-12-28 08:00 ET
iBio published news for 2020 q3
SEC form 6
2020-12-23 16:31 ET
iBio published news for 2020 q3
SEC form 6
2020-12-10 17:06 ET
iBio published news for 2020 q3
SEC form 6
2020-12-09 16:33 ET
iBio published news for 2020 q3
SEC form 6
2020-12-07 08:36 ET
iBio published news for 2020 q3
SEC form 6
2020-11-25 17:10 ET
iBio published news for 2020 q3
SEC form 6
2020-11-24 07:40 ET
iBio published news for 2020 q3
SEC form 10
2020-11-16 16:16 ET
iBio published news for 2020 q3
SEC form 6
2020-11-16 16:10 ET
iBio published news for 2020 q3
SEC form 6
2020-11-03 17:21 ET
iBio published news for 2020 q3
SEC form 6
2020-11-03 07:45 ET
iBio published news for 2020 q3
SEC form 6
2020-10-27 17:00 ET
iBio published news for 2020 q3
SEC form 6
2020-10-23 17:21 ET
iBio published news for 2020 q3
SEC form 6
2020-10-22 16:05 ET
iBio published news for 2020 q3
SEC form 6
2020-10-16 16:05 ET
iBio published news for 2020 q3
SEC form 10
2020-10-13 17:17 ET
iBio published news for 2020 q2
SEC form 6
2020-10-13 16:27 ET
iBio published news for 2020 q3
SEC form 6
2020-10-13 07:00 ET
iBio published news for 2020 q3
SEC form 6
2020-10-09 16:30 ET
iBio published news for 2020 q3
SEC form 6
2020-10-05 08:01 ET
iBio published news for 2020 q3
SEC form 6
2020-10-02 07:30 ET
iBio published news for 2020 q3